Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.53 |
| ▸ | PTPRF | P10586 | 2/20 | 0.40 |
| ▸ | PTPRA | P18433 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579699 | 0.91 | PTPN1 (0.61) | PTPN1PTPRFPTPRADUSP3PTPRC | |
| SCHEMBL6584826 | 0.81 | PTPN1 (0.59) | PTPN1PTPRFPTPRADUSP3PTPRC | |
| SCHEMBL6579618 | 0.80 | PTPN1 (0.68) | PTPN1PTPRFPTPRADUSP3PTPRC | |
| SCHEMBL4670290 | 0.80 | PTPN1 (0.53) | PTPN1NPC1L3MBTL1 | |
| SCHEMBL4672318 | 0.79 | PTPN1 (0.51) | PTPN1PPARGPPARANCEH1 | |
| SCHEMBL4672323 | 0.79 | PTPN1 (0.49) | PTPN1PPARGPPARANCEH1 | |
| SCHEMBL4274615 | 0.79 | SMN1; SMN2 (0.43) | PTPN1DUSP3NPC1PPARGPPARA | |
| SCHEMBL4672430 | 0.79 | PTPN1 (0.57) | PTPN1L3MBTL1PPARGNCEH1ABCG2 | |
| SCHEMBL4271620 | 0.78 | PTPN1 (0.42) | PTPN1PPARGPPARA | |
| SCHEMBL4670266 | 0.76 | PTPN1 (0.69) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | PTPN1 1287/4885PTPRF 1766/4885PTPRA 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.